Board summary
Key figures
62,572
Registered population
60.3% aged 18–64
14.7%
Aged 65+
ICB 19.9% · England 17.9%
23.7%
Ethnic minority (non-White)
9.3% Asian · England 9.6%
10.2%
In IMD quintile 1
ICB 17.1% · England 21.0%
~5,226
Core20 residents (est.)
Resident basis; registered basis ~6,416 · see page 3
8,287
Hypertension register
+9.32% in 3 yrs · England +5.60%
392
SMI register
35.4% of Dartford's
932
COPD register
Reviews -10.30% in 3 yrs
Forecast to 2030
11,586
Hypertension patients, 2030
+3,299 on today
68.8%
QRISK ≥20% on statins, 2030
+5.39pp over 3 yrs
3.8%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Core20 deprivation is concentrated in two practices.
Practice Core20 shares span 14.9 pp: Swanscombe Health Centre has 14.9% (5,591 estimated patients), Pilgrims Way Surgery 9.0% (825), and Downs Way Medical Practice.
Asthma annual review coverage fell over three years.
Asthma review coverage is 67.0% (about 910 unreviewed), having fallen 8.5% over 2023 to 2025 against England (+4.4%), which may reflect recall strain.
Population, age and ethnicity
Projected list growth of 13.3% coincides with a young demographic and diverse communities
Garden City PCN registers 62,572 patients, with 25.0% aged 0-17 against 23.3% in Dartford, 20.7% in NHS Kent and Medway ICB, and 19.6% in England. Those aged 65+ represent 14.7% (Dartford 15.1%, ICB 19.9%, England 17.9%). Associated Census usual residents show a 23.7% ethnic minority share, including 9.3% Black residents (Dartford 10.5%, ICB 3.1%, England 4.2%), rather than registered-patient ethnicity. Practice-area Black resident shares span from 14.3% at Pilgrims Way Surgery to 2.1% at Downs Way Medical Practice. Unverified product forecasts project 13.3% list growth to 2030 (Dartford 9.1%, ICB 6.0%, England 2.3%).
Age profile
65+: ICB 19.9%, England 17.9%
Ethnicity
Older people · falls rows are Dartford local-authority (LA) data, not PCN
| Measure | Local | South East | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Dartford LA) | 2,006 | 2,018 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 79.9% | 82.2% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 53.5% | 57.8% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Dartford LA) | 1,000 | 981 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Dartford LA) | 14.2 | 14.0 | 14.8 | 2022‑24 |
Deprivation and Core20
Deprivation averages decile 6.0 overall but practice Core20 shares vary across 14.9 pp
Garden City PCN averages IMD decile 6.0 (Dartford 6.0, NHS Kent and Medway ICB 5.4, England 5.5) with a 10.2% Core20 registered share, above Dartford (9.8%) but below NHS Kent and Medway ICB (17.1%) and England (21.0%). Practice shares span 14.9 pp: Swanscombe Health Centre records 14.9% (5,591 estimated patients) and Pilgrims Way Surgery 9.0% (825), whereas Downs Way Medical Practice records 0.0%. Practice estimates sum to 6,416 registered patients against 5,226 associated residents in deciles 1 and 2. Reconciling these count bases ensures outreach targets the highest-need practices effectively.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
392
SMI register
0.64% recorded prevalence
247
Learning disability register
0.40% recorded prevalence
18
Care homes, 725 beds
In the PCN catchment
8.6%
Provide unpaid care
Dartford, Census 2021
Recorded learning disability prevalence is 0.4% (247 patients) and severe mental illness is 0.6% (392 patients), both below Dartford, ICB, and England rates (0.6% for learning disability; 0.8%, 0.9%, and 1.0% for mental illness). The catchment includes 18 care homes with 725 beds, though capacity does not establish registered residency. Lower recorded prevalence may reflect diagnostic variation, unverified locally and testable by practice register audits.
Severe mental illness: physical health checks
SMI recorded prevalence is 0.6% (England 1.0%). Annual physical checks trail England across individual elements: blood pressure checks reached 75.5% (England 83.4%) and BMI recording 72.6% (England 82.1%). Routine physical monitoring requires systematic recall across all check components.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
8,287
Hypertension register
+9.32%
Register growth, 3 yrs
Dartford +7.12% · England +5.60%
−3.17pp
BP control, under 80
≤140/90 · −0.16pp aged 80+
+3,299
More patients by 2030
Forecast 11,586 (16.20%)
Hypertension case-finding and control
The hypertension register numbers 8,287 patients, representing 13.6% recorded prevalence, below England (15.2%), Dartford (15.9%) and NHS Kent and Medway ICB (16.2%). Although the register grew +9.3% over 2023 to 2025 (England +5.6%), recent blood pressure checks stand at 84.8% (England 90.0%; 3-year change -2.8% vs England +3.6%). Furthermore, blood pressure control in patients aged under 80 stands at 63.5% (3-year change -4.8% vs England +3.2%; England 67.8%), ranging across practices from 61.9% at Swanscombe Health Centre and 62.6% at Pilgrims Way Surgery to 67.9% at Downs Way Medical Practice. Blood pressure monitoring and clinical control lag national rates, indicating an opportunity to prioritise systematic recall and home monitoring for under-controlled patients.
Lipids and statins
Lipid-lowering therapy reaches 56.3% of patients with QRISK ≥ 20%, below England (63.6%) and Dartford (64.2%). Statin coverage in diabetes without cardiovascular disease also lags at 67.1% (England 73.2%). Fewer at-risk patients receive primary prevention lipid therapy than nationally, pointing to a clear need to prioritise proactive cardiovascular risk reviews.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 87,577 | £1.50 | £1.90 | £1.86 | £131,366 |
| Cardiovascular (all), 2025 | 125,431 | £3.36 | £3.57 | £3.33 | £421,448 |
In 2026, the PCN prescribed 87,577 lipid-regulating drug items at £1.50 per item, below England (£1.86), Dartford (£1.79) and NHS Kent and Medway ICB (£1.90), spending £31,528 less than at England's unit cost. Unit costs sit below national levels, suggesting clinical teams can prioritise closing initiation gaps in high-risk patients over expenditure controls.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
−8.54%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
+4.95%
Asthma prevalence, PCN 3-yr % change
Asthma recorded prevalence is 4.9% (2,773 patients) and COPD is 1.5% (932 patients), both below England (6.6% and 1.9%). While asthma annual review coverage is 67.0% (England 65.7%), three-year change was -8.5% over 2023 to 2025 (England +4.4%), leaving about 910 patients without a recorded review. COPD reviews reached 68.9% (England 76.4%), with three-year change of -10.3% (England +2.8%). Slower review rates may reflect recall strain, unverified locally, requiring prioritized clinical searches.
Cancer register and children's immunisation
Cancer prevalence is 3.4% (2,057 patients; England 3.8%). In Q1 2025/26 childhood immunisations, pre-school coverage trails targets: MMR dose 1 reached 90.1% at age 5 but dose 2 reached 81.7%, creating an 8.4 pp same-cohort dose difference. Pre-school 4-in-1 booster coverage is 80.2% (England 80.9%), below the 95.0% target by 14.8 pp. Scheduling gaps between primary and pre-school boosters risk unprotected cohorts entering school.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
55.6%
Kent and Medway ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~1,630
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Kent and Medway ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Breast | 82.1% | 85.4% | 23% | 1,509 |
| Prostate | 54.4% | 53.2% | 37% | 1,435 |
| Lung | 29.4% | 33.8% | 21% | 1,109 |
| Bowel | 48.2% | 47.0% | 29% | 1,013 |
| Skin cancer | 87.5% | 87.8% | 23% | 562 |
In NHS Kent and Medway ICB, 55.6% of staged cancers (4,661 of 8,384) were diagnosed at stage 1 or 2 in 2022 (England 55.3%), with a distance of -19.4 pp to the 75.0% national ambition by 2028. Known-stage coverage was 63.6% (8,384 of 13,189; England 67.0%), representing 1,627 extra early-stage cases a year to reach 75% across the ICB; staging was not captured at PCN level. For GARDEN CITY PCN, cervical screening coverage is 68.7% (England 66.8%, ICB 69.9%), with 65.7% at Swanscombe Health Centre and 74.8% at Downs Way Medical Practice. PCN breast screening coverage is 68.0% (England 69.9%).
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In July 2026, Dartford and Gravesham NHS Trust achieved 78.1% on the 28-day faster diagnosis standard (standard 75.0%; King's College Hospital NHS Foundation Trust 80.7%, NHS Kent and Medway Integrated Care Board 76.8%, England 79.3%) and 97.5% on 31-day treatment (standard 96.0%). The 62-day referral to treatment rate was 63.6%, showing a distance of -21.4 pp to the 85.0% standard (King's College Hospital 70.1%, ICB 75.9%, England 71.2%). Diagnostic 6-week waits stood at 8.4% (England 23.1%). These provider metrics describe acute system performance rather than PCN delivery.
| Pathways within standard (%) | Dartford and Gravesham | King's College | Kent and Medway ICB | England |
|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 78.14 | 80.68 | 76.78 | 79.32 |
| 31-day treatment (96%) | 97.48 | 96.68 | 95.84 | 92.50 |
| 62-day referral to treatment (85%) | 63.59 | 70.15 | 75.93 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Dartford and Gravesham | Kent Health | King's College | England |
|---|---|---|---|---|
| MRI | 0.36 | — | 21.22 | 21.40 |
| CT | 2.08 | — | 22.60 | 9.92 |
| Echocardiography | 3.90 | — | 14.39 | 28.48 |
| Colonoscopy | 0.40 | — | 41.81 | 30.83 |
| Gastroscopy | 0.00 | — | 35.98 | 29.02 |
| All 15 DM01 tests | 8.37 | 27.49 | 19.15 | 23.14 |
| Community services activity | Kent residents | Kent and Medway ICB |
|---|---|---|
| Care contacts | 210,170 | 254,055 |
| Referrals | 59,360 | 68,085 |
| Patients with a contact | 60,605 | 72,060 |
Community services (residents of Kent), Jun 2026 (provisional). In June 2026, Kent recorded 210,170 community care contacts across 265,905 care activities, covering 60,605 patients. NHS Kent and Medway Integrated Care Board recorded 254,055 contacts and 297,595 activities. Community contacts with adults aged 65+ accounted for 65.8% of Kent residents' contacts (138,250). These provisional local authority and ICB figures reflect wider community activity, not PCN-level care.
Practice variation and patient experience
Phone access spans 18.3 pp and vaccination achievement spans 36.2 pp across practices
In 2025/26, QOF clinical achievement reached 100.0% at Swanscombe Health Centre, 100.0% at Downs Way Medical Practice, and 99.8% at Pilgrims Way Surgery (England 97.1%). In contrast, vaccination and immunisation achievement spans a 36.2 pp range, from 16.4% at Pilgrims Way Surgery and 21.1% at Swanscombe Health Centre to 52.5% at Downs Way Medical Practice (England 55.2%).
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Swanscombe | 111 | 14.9 | 23.0% | 75.8% | 71.4% |
| Downs Way Medical | 111 | 0.0 | 36.3% | 63.2% | 69.1% |
| Pilgrims Way | 103 | 9.0 | 41.3% | 71.0% | 61.8% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Fourteen of 25 compared measures trail England over three years, led by reviews
Fourteen of 25 compared measures trail England's three-year change over 2023 to 2025. Trailing trajectories concentrate in routine annual reviews: heart failure reviews fell 6.2% (England +8.7%), COPD reviews fell 10.3% (England +2.8%), and asthma reviews fell 8.5% (England +4.4%), alongside under-80 blood pressure control falling 4.8% (England +3.2%). Conversely, three-year gains include severe mental illness alcohol recording rising 20.5 pp (England +5.4 pp) and BMI checks rising 14.0 pp (England +5.1 pp). This divergence may reflect uneven recall capacity, unverified locally and testable by clinical audit.
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Heart failure reviews
COPD reviews
Asthma reviews
BP control, under 80
Hypertension treated to target
Alcohol record (psychosis)
Breast screening (53-70)
BMI record (SMI)
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Dartford | Asset | PCN | Dartford |
|---|---|---|---|---|---|
| Care homes (catchment) | 18 (725 beds) | n/a | Schools (catchment) | 113 | n/a |
| Children's centres | 8 | 7 | Places of worship | 57 | 41 |
| Libraries | 7 | 7 | Food banks (VCS) | 1 | no data |
| Homelessness support (VCS) | n/a | 1 | Day centres (VCS) | 9 | 5 |
| Children and young people (VCS) | 1 | 1 | Carers support groups (VCS) | n/a | 3 |
| Primary schools (LA maintained) | 11 | 6 | Primary academies | 22 | 22 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Asthma annual review recall catch-up
Asthma review coverage is 67.0% of the 2,773 register (England 65.7%), but fell 8.5% over 2023 to 2025 (England +4.4%), leaving 914 (about 910) unreviewed. For discussion: run a single-template asthma recall search with flexible review slots, starting in the highest-deprivation practices. Low cost, quick to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 2
Hypertension control and lipid review
On the 8,287 hypertension register (13.6% vs England 15.2%), under-80 BP control is 63.5% (England 67.8%, down 4.8% over 2023 to 2025 vs England +3.2%) and QRISK ≥ 20% lipid therapy is 56.3% (England 63.6%). Moderate effort to run.
Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.
Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).
Option 3
Learning disability register validation
Recorded learning disability prevalence is 0.4% (247 patients) against 0.6% in Dartford, NHS Kent and Medway ICB, and England, a benchmark range of +106 to +121 patients (121 against England). For discussion: audit clinical records for uncoded learning disability diagnoses and review annual health check invitations. Low cost, quick to run.
Evidence base: the register is the cohort for the annual health check and LeDeR learning; people with a learning disability die on average 20 years earlier and are a Core20PLUS5 PLUS group.
Policy anchor: annual health checks for 75% of people aged 14+ on the register (Network Contract DES); Oliver McGowan mandatory training.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Diverse community access review (p2) | Black / African / Caribbean / Black British | Neighbourhood health framework · Core20PLUS5 approach | PCN |
| Two-track Core20 outreach (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| Severe mental illness physical checks (p4) | SMI register with a BP check in the last 12 months | MHIS · From Harm to Hope | PCN |
| Hypertension control recall audit (p5) | Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Pre-school booster recall catch-up (p6) | MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Cervical screening equity outreach (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
| Practice telephony and triage review (p9) | GPPS easy to contact the practice by phone | 10YHP, hospital to community | Practice |
| Option 1 · Asthma annual review recall catch-up (p12) | Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) | Core20PLUS5 respiratory | PCN |
| Option 2 · Hypertension control and lipid review (p12) | Hypertension register · Hypertension: QOF prevalence · Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN & Practice |
| Option 3 · Learning disability register validation (p12) | Learning disability register · Learning disability: QOF prevalence | 75% annual health checks (Network Contract DES) · Oliver McGowan | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | ICB | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
